[1]Wyatt RJ, Julian BA. IgA Nephropathy[J]. New Engl J Med,2013,368(25):2402-2414.
[2]郭宗运,王营营,李慧,等.表现为微量白蛋白尿IgA肾病预后的危险因素分析[J].中国医师杂志,2015,17(11):1694-1697.
[3]陈香美,谢院生. 重视延缓IgA肾病进展的基础和临床研究[J].中华肾脏病杂志,2004,20(4):1-3.
[4]D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome[J]. Semin Nephrol,2004,24(3):179-196.
[5]Moriyama T, Itabashi M, Takei T, et al. High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a[J]. J Nephrol,2015,28(4):451-456.
[6]Moriyama T, Tanaka K, Iwasaki C, et al.Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan[J]. PLoS One,2014,9(e917563):doi: 10.1371/journal.pone.0091756. eCollection 2014.
[7]Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population[J]. Nephrol Dial Transplant,2012,27(4):1479-1485.
[8]陈颖越,金星,丁波,等. 2型糖尿病患者尿酸与大血管病变的相关性分析[J].医学研究生学报,2014,27(2):221-222.
[9]矫树华,刘鹏亮,温艳惠. 脂肪肝与血脂、血糖、血尿酸及血清铁蛋白的相关性分析[J].东南国防医药,2015,17(3):275-277.
[10]陈涛,李卫,王杨,等.高尿酸血症的患病情况及相关因素分析[J].中华临床医师杂志(电子版),2012,6(13):3526-3529.
[11]蔡伟程,韩蜀莲,郭晓丹,等. IgA肾病合并高尿酸血症患者的临床病理分析[J].临床肾脏病杂志,2016,16(3):152-156.
[12]田耘,卓莉,李文歌,等. 149例IgA肾病合并高尿酸血症的临床和病理特点[J].北京医学,2012,34(4):257-259.
[13]樊星,韩鸿玲.IgA肾病伴高尿酸血症与肾脏病理改变的关系[J].实用医学杂志,2016,32(12):2014-2017.
[14]段晓雯,王利华,邵金金,等. IgA肾病患者合并高尿酸血症临床及病理特征分析[J].中华肾病研究电子杂志,2016,5(2):70-74.
[15]Baradaran A. Renal vascular lesions in IgA nephropathy[J]. J Renal Inj Prev,2013,2(2):37-38.
[16]Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial[J]. JAMA,2008,300(8):924-932.
[17]Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis[J]. BMC Nephrol,2015,16(58):doi: 10.1186/s12882-015-0047-z.
[18]师素芳,张宏.对于IgA肾病牛津病理分型验证现状的分析[J].中华肾脏病杂志,2012,28(3):167-169.
[19]Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments[J]. Kidney Int,2014,86(4):828-836.
[20]李卅立. IgA肾病牛津分型与临床指标的相关危险因素分析[D].中国医科大学,2013.
[21]Zhou J, Chen Y, Liu Y, et al. Plasma uric acid level indicates tubular interstitial leisions at early stage of IgA nephropathy[J]. BMC Nephrol,2014,15:11. doi: 10.1186/1471-2369-15-11.
[22]Mulay SR, Evan A, Anders H. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease[J]. Nephrol Dial Transpl,2014,29(3):507-514.
[23]Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy[J]. Adv Ther,2015,32(12):1177-1191.
[1]杨 黄.IgA肾病患者血压节律和血浆B型钠尿肽变化的临床价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(04):349.[doi:10.3969/j.issn.1672-271X.2013.04.010]
YANG Huang.The clinical value of blood pressure rhythm and plasma B-type natriuretic peptide in patients with IgA nephropathy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(06):349.[doi:10.3969/j.issn.1672-271X.2013.04.010]
[2]陈学香,夏向南,张丹奋,等.金线莲胶囊治疗高龄老年人高尿酸血症36例[J].医学研究与战创伤救治(原医学研究生学报),2010,12(04):331.
[3]黄海,列才华,梁兰青,等.细胞因子对IgA肾病患者IgA1 O-糖基化的影响及相关机制研究[J].医学研究与战创伤救治(原医学研究生学报),2019,21(01):44.[doi:10.3969/j.issn.1672-271X.2019.01.010]
HUANG Hai,LIE Cai-hua,LIANG Lan-qing,et al.Effects of cytokines on IgA1 O-glycosylation in IgAN and its related mechanisms[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(06):44.[doi:10.3969/j.issn.1672-271X.2019.01.010]
[4]张沛,周昱,高春林,等.咪唑立宾联合糖皮质激素治疗儿童IgA肾病的临床研究[J].医学研究与战创伤救治(原医学研究生学报),2022,24(4):356.[doi:10.3969/j.issn.1672-271X.2022.04.005]
ZHANG Pei,ZHOU Yu,GAO Chun-lin,et al.Clinical research of mizoribine in the treatment of children with IgA nephropathy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(06):356.[doi:10.3969/j.issn.1672-271X.2022.04.005]